Psychedelic drugs like psilocybin and MDMA show promise for treating depression, with research indicating swift-acting and enduring effects. Despite the FDA’s rejection of an MDMA-based therapy last August, the potential for mainstream medical use remains strong. Compass Pathways, a biotech company, is researching psilocybin, though trials are complex. If approved by the FDA, a significant legal medical market could emerge. Scott Marshall, head of mycology at Optimi Health in British Columbia, Canada, is one of the few licensed psilocybin mushroom cultivators in North America. Since joining Optimi in 2022, he has grown over 500 pounds of mushrooms, with most stored in the company’s vault due to limited legal markets. Optimi received a $22 million investment and a drug establishment license in 2024 to export pharmaceutical-grade psilocybin. Countries like Oregon and Australia are exploring legal avenues for psychedelic therapy, reflecting a growing acceptance of these treatments.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
